News

News Nov 21, 2025

The Week in Review in Prescription Drug Pricing: USPTO Undermines Biosimilar Competition, Pharma Pushing PERA, New Public Citizen Report, and more

The United States Patent and Trademark Office (USPTO) is considering a new rule that would make it harder for biosimilar manufacturers and patient advocacy groups to challenge drug patents through…

Read Article News Nov 14, 2025

The Week in Review in Prescription Drug Pricing: Uncertainty Around MFPs with GLP-1 Deal, What We’re Watching with Congress Back, and more

With President Trump’s GLP-1 pricing deals dominating headlines, the ongoing Medicare negotiation program appears to have taken a backseat — despite the fact that the second round of maximum fair…

Read Article News Nov 7, 2025

The Week in Review in Prescription Drug Pricing: WH Deal on Weight Loss Drugs, Novo’s DTC Searches, AZ Downplays MFN, FDA on Gene Editing Therapy

From the Oval Office on Thursday, President Trump announced lower prices on several blockbuster weight-loss drugs, including Ozempic, Wegovy, and Zepbound, for patients on Medicare, as well as for…

Read Article News Oct 31, 2025

The Week in Review in Prescription Drug Pricing: FDA Announcement, Cigna Ends Drug Rebates, Senate HELP Hearing, P4AD Merch, and more!

The FDA took a significant step in accelerating biosimilar approvals this week, announcing a new draft guidance to cut unnecessary red tape and streamline duplicative clinical trial requirements.

Read Article News Oct 24, 2025

The Week in Review in Prescription Drug Pricing: ORPHAN Re-Score as P4ADNow & AARP Urge Congress Against EPIC, Pharma Lobbying, and New I-MAK Survey

The re-score of the ORPHAN Cures Act by the Congressional Budget Office (CBO) confirmed what patients feared: the bill is even more expensive and more harmful than originally projected.

Read Article News Oct 17, 2025

The Week in Review in Prescription Drug Pricing: AstraZeneca Strikes Deal with Trump, While Undermining Admin’s Powers Behind the Scenes, All Eyes On CMS, Pharma Fact Check and more

The Trump administration announced that AstraZeneca struck a deal to sell certain drugs to Medicaid at a discount, and committed to listing any new drugs it releases on the TrumpRx platform.

Read Article News Oct 14, 2025

The Week in Review in Prescription Drug Pricing: Amgen’s New DTC Program, Another Pharma Court Loss, Colorado News, P4AD at IRA Conference, and more

Nearly two weeks after President Trump’s TrumpRx announcement, Amgen unveiled its own direct-to-consumer (DTC) program, announcing a discounted price for its cholesterol drug, Repatha, at $239 per…

Read Article News Oct 3, 2025

The Week in Review in Prescription Drug Pricing: TrumpRx Announced, ORPHAN Re-score Anticipated Soon, New Profile on P4AD Patient Advocates, and more

Even in a crowded week of news, prescription drug pricing remained prominent with President Trump’s announcement of TrumpRx — a new government direct-to-consumer platform — alongside a deal with…

Read Article News Sep 26, 2025

The Week in Review in Prescription Drug Pricing: P4AD Files 5th Amicus Brief as Pharma Petitions SCOTUS, Hikes Abroad, KFF Slams ORPHAN, and more

On Wednesday, P4AD filed its fifth patient-centered amicus brief defending the Medicare Negotiation Program, this time against PhRMA’s appeal to the Fifth Circuit.

Read Article News Sep 19, 2025

The Week in Review in Prescription Drug Pricing: 14th Court Victory, MFN Letter Deadline Approaches, FDA Commissioner on DTC Ads, and more!

In a unanimous decision, the Third Circuit U.S. Court of Appeals rejected Novartis’ challenge and stood with Medicare negotiation, exactly one week after the same court delivered a similar defeat to…

Read Article